Drug Trial Radar · NCT04143594
Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV
Last checked: Nov 19, 2026Latest source record: Oct 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
183
Actual
Start
Nov 22, 2019
Primary completion
Oct 5, 2021
Study completion Sep 19, 2023
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Oct 29, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy of lenacapavir (formerly GS-6207) containing regimens in people living with human immunodeficiency virus (HIV) (PLWH).
Conditions
- HIV-1-infection
Interventions
Oral LenacapavirDrug
Tablets administered without regard to food
F/TAFDrug
Tablets administered without regard to food
Subcutaneous LenacapavirDrug
Administered in the abdomen via subcutaneous injections
TAFDrug
Tablets administered without regard to food
BICDrug
Tablets administered without regard to food
B/F/TAFDrug
Tablets administered without regard to food
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 54 as Determined by the United States Food and Drug Administration (US FDA)-Defined Snapshot AlgorithmTime frame: Week 54
Locations
53 sites in 3 countries. Site status is shown where the registry gives one.
Valleywise Community Health Center - McDowell
Phoenix, Arizona
Pueblo Family Physicians
Phoenix, Arizona
Ruane Clinical Research Group Inc
Los Angeles, California
Mills Clinical Research at Men's Health Foundation
Los Angeles, California
Eisenhower Health Center at Rimrock
Palm Springs, California
University of Colorado, Denver, University of Colorado Hospital
Aurora, Colorado
Denver Public Health
Denver, Colorado
Yale University; School of Medicine
New Haven, Connecticut
Georgetown University Hospital
Washington D.C., District of Columbia
Whitman-Walker Institute, Inc.
Washington D.C., District of Columbia
Washington Health Institute
Washington D.C., District of Columbia
Midland Florida Clinical Research Center, LLC
DeLand, Florida
Midway Immunology and Research Center
Ft. Pierce, Florida
Floridian Clinical Research
Hialeah, Florida
AHF-The Kinder Medical Group
Miami, Florida
AIDS Healthcare Foundation - South Beach
Miami Beach, Florida
Orlando Immunology Center
Orlando, Florida
St. Joseph's Hospital Comprehensive Research Institute
Tampa, Florida
Triple O Research Institute, P.A.
West Palm Beach, Florida
Atlanta ID Group, PC
Atlanta, Georgia
August University Medical Center
Augusta, Georgia
Infectious Disease Specialists of Atlanta
Decatur, Georgia
Mercer University, Department of Internal Medicine
Macon, Georgia
Chatham County Health Department
Savannah, Georgia
Howard Brown Health Center
Chicago, Illinois
Northstar Healthcare
Chicago, Illinois
Indiana University Infectious Diseases Research
Indianapolis, Indiana
Be Well Medical Center
Berkley, Michigan
St. John Newland Medical Associates
Southfield, Michigan
KC CARE Health Center
Kansas City, Missouri
AHF-Midtown
New York, New York
Montefiore Medical Center
The Bronx, New York
East Carolina University, The Brody School of Medicine
Greenville, North Carolina
Rosedale Infectious Diseases
Huntersville, North Carolina
University of Cincinnati
Cincinnati, Ohio
Case Clinical Research Site/University Hospitals Cleveland Medical Center
Cleveland, Ohio
The Ohio State University Medical Center
Columbus, Ohio
Allegheny Health Network
Pittsburgh, Pennsylvania
St. Jude Children's Research Hospital
Memphis, Tennessee
Central Texas Clinical Research
Austin, Texas
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.